LS CancerDiag, a leader in early Lynch syndrome detection, proudly announces its rebrand to Lynsight. This represents the next step in the company’s journey to introduce a new method for Lynch syndrome testing to the global market.
For over 10 years, Lynsight has been at the forefront of Lynch syndrome research, driven by a mission to find better ways to help people detect and treat cancer. Originating from an invention developed at the labs of the University of Helsinki in the 1990s, Lynsight’s relentless pursuit to provide the most precise cancer diagnostics continues every day. The company is committed to ensuring that every potential Lynch syndrome case is tested.
The DiagMMR test has been developed to identify Lynch syndrome in all suspected persons, regardless of whether they are healthy or cancer patients. With the new name and rebranding, we can now clearly emphasize its importance as a cancer preventive test.
Minna Nyström
Founder & Chairman of the Board
Lynsight’s assay, DiagMMR, tests for MMR deficiency, giving providers and patients a clearer picture about the presence of Lynch syndrome. Lynsight’s vision is to make DiagMMR the new global standard test for Lynch syndrome and support the early detection of the disease – even before tumors develop. The company’s mission is to empower families and healthcare professionals to make better-informed decisions for cancer detection and treatment.
Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With an estimated 1 in 300 people of the world’s population being affected by Lynch syndrome, there are millions of people at a significantly high lifetime risk for cancer. That’s where DiagMMR from Lynsight comes in.
We are excited to introduce DiagMMR to the global market. Our functional test marks a major advancement in Lynch syndrome diagnostics, delivering unparalleled accuracy and clarity by directly measuring inherited MMR deficiency. With DiagMMR, we are empowering healthcare providers and patients with the critical information they need for the prevention and early detection of cancer.
As the CEO of Lynsight, I trust our rebranding signifies our dedication to revolutionizing cancer prevention and diagnostics, further improving health outcomes worldwide.
Niklas Lahti
Chief Executive Officer
Lynsight is excited to continue its journey towards a future where early and precise Lynch syndrome detection with its technology becomes a global standard of care. Its rebranding is not just a change of name but a reaffirmation of its commitment to Lynch syndrome diagnostics and cancer prevention. Lynsight will bring patients and families, healthcare providers and the broader healthcare community the clear answers they’ve been hoping for, and significantly impact global health, one test at a time.
More information on the new brand will be announced soon. You can have a first look by exploring here. For updates on DiagMMR’s availability, please sign up for the newsletter.
Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With an estimated 1 in 300 people of the world’s population being affected by Lynch syndrome, there are millions of people at a significantly high lifetime risk for cancer. That’s where DiagMMR from Lynsight comes in.
About Lynsight
Lynsight is at the forefront of Lynch syndrome research, driven by the mission to find a better way to help people prevent cancer. With its functional test, DiagMMR, Lynsight offers a new way to test for Lynch syndrome, so healthcare providers and families can focus on the path instead of the problem. DiagMMR tests for MMR deficiency, providing a clearer picture about the presence of Lynch syndrome. Based on over 25 years of research, DiagMMR has demonstrated high specificity and sensitivity.
Lynsight is headquartered in Helsinki, Finland, and the company is working on making DiagMMR accessible across the world. Stay up to date with DiagMMR’s availability and other Lynch syndrome resources here.
